Rapport Therapeutics, Inc.
RAPPNasdaq
$42.62
↑ +6.2%Jul 17 close · end-of-day
Price
1Y↑ +180.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0B
Enterprise Value
$1.5B
P/E
—
P/S
—
P/B
4.3
EV/EBITDA
—
PEG
—
FCF Yield
-4.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$107.3M
Free Cash Flow (TTM)
-$80.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-22.8%
ROIC
—
Debt / Equity
—
Net Cash
$476.8M
Return 1Y
+187.2%
Company profile
We are a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders. We were incorporated under the laws of the State of Delaware in February 2022 under the name Precision Neuroscience NewCo, Inc., and changed our name to Rapport Therapeutics, Inc. in October 2022. Our principal executive offices are located at 1325 Boylston Street, Suite 401, Boston, MA. We have one subsidiary, Rapport Therapeutics Securities Corporation, formed in December 2022 under the laws of the Commonwealth of Massachusetts.
- CEO
- Abraham N. Ceesay
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Massachusetts
- Website
- www.rapportrx.com
Management & directors
- Ceesay AbrahamChief Executive Officer
- Gault CherylChief Operating Officer
- Yeleswaram KrishnaswamyChief Development Officer
- Bredt DavidChief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
RAPP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20.0M—
Diluted EPS-$0.42↓ -38.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$36.2M | -$83.1M | -$125.1M |
| Net income | -$34.8M | -$78.3M | -$111.5M |
| Diluted EPS | -$23.10 | -$3.78 | -$2.86 |
| Operating cash flow | -$27.2M | -$64.8M | -$87.5M |
| Free cash flow | -$28.8M | -$67.2M | -$88.1M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — | — | — | $20.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$20.8M | -$21.6M | -$23.5M | -$27.1M | -$29.5M | -$30.0M | -$38.5M | -$24.2M |
| Net income | -$18.1M | -$17.5M | -$20.0M | -$24.1M | -$26.7M | -$26.9M | -$33.8M | -$19.9M |
| Diluted EPS | -$1.70 | -$0.50 | $9.49 | -$0.68 | -$0.75 | -$0.71 | -$0.72 | -$0.42 |
| Operating cash flow | -$16.4M | -$16.4M | -$14.4M | -$20.2M | -$25.1M | -$17.5M | -$24.7M | -$13.1M |
| Free cash flow | -$17.3M | -$16.6M | -$14.7M | -$20.5M | -$25.1M | -$17.6M | -$24.9M | -$13.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -121.1% |
| Net margin | — | — | — | — | — | — | — | -99.3% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Ceesay Abraham· Chief Executive Officer | Sale | 5,481 | $39.72 | $217,714.64 | filing |
| 2026-07-14 | Ceesay Abraham· Chief Executive Officer | Sale | 2,729 | $40.57 | $110,722.08 | filing |
| 2026-06-30 | Gault Cheryl· Chief Operating Officer | Sale | 3,792 | $41.39 | $156,963.77 | filing |
| 2026-06-30 | Gault Cheryl· Chief Operating Officer | Sale | 3,308 | $42.17 | $139,505.64 | filing |
| 2026-06-30 | Gault Cheryl· Chief Operating Officer | Sale | 1,900 | $40.09 | $76,173.66 | filing |
| 2026-06-30 | Gault Cheryl· Chief Operating Officer | Sale | 1,000 | $43.15 | $43,154.70 | filing |
| 2026-06-29 | Ceesay Abraham· Chief Executive Officer | Sale | 7,344 | $39.77 | $292,062.07 | filing |
| 2026-06-29 | Ceesay Abraham· Chief Executive Officer | Sale | 876 | $40.34 | $35,335.65 | filing |
| 2026-05-26 | Third Rock Ventures V, L.P. | Sale | 18,572 | $40.05 | $743,752.88 | filing |
| 2026-05-11 | Third Rock Ventures V, L.P. | Sale | 133,618 | $40.24 | $5.4M | filing |
| 2026-05-08 | Third Rock Ventures V, L.P. | Sale | 5,018 | $40.31 | $202,255.51 | filing |
| 2026-05-07 | Third Rock Ventures V, L.P. | Sale | 271,495 | $40.12 | $10.9M | filing |
| 2026-04-17 | Third Rock Ventures V, L.P. | Sale | 426,005 | $40.32 | $17.2M | filing |
| 2026-04-17 | Yeleswaram Krishnaswamy· Chief Development Officer | Sale | 20,225 | $39.99 | $808,844.27 | filing |
| 2026-04-14 | Yeleswaram Krishnaswamy· Chief Development Officer | Sale | 10,200 | $35.08 | $357,796.62 | filing |
| 2026-04-13 | Yeleswaram Krishnaswamy· Chief Development Officer | Sale | 9,165 | $34.97 | $320,536.71 | filing |
| 2026-04-10 | Yeleswaram Krishnaswamy· Chief Development Officer | Sale | 500 | $34.98 | $17,490.00 | filing |
| 2026-04-08 | Yeleswaram Krishnaswamy· Chief Development Officer | Sale | 360 | $34.90 | $12,564.00 | filing |
| 2026-03-30 | Gault Cheryl· Chief Operating Officer | Sale | 7,161 | $28.04 | $200,795.16 | filing |
| 2026-03-30 | Gault Cheryl· Chief Operating Officer | Sale | 2,839 | $28.55 | $81,061.97 | filing |
| 2026-03-25 | Yeleswaram Krishnaswamy· Chief Development Officer | Sale | 10,115 | $29.99 | $303,354.92 | filing |
| 2026-03-05 | Gault Cheryl· Chief Operating Officer | Sale | 2,014 | $28.93 | $58,265.02 | filing |
| 2026-02-19 | Bredt David· Chief Scientific Officer | Option exercise | 6,000 | $1.80 | $10,800.00 | filing |
| 2026-02-18 | Ceesay Abraham· Chief Executive Officer | Sale | 3,552 | $29.05 | $103,191.28 | filing |
| 2026-02-18 | Ceesay Abraham· Chief Executive Officer | Sale | 2,983 | $29.04 | $86,639.15 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.